Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5387 ARTÍCULOS , VIENDO DEL 4336 AL 4350

Impact of intensive upper limb rehabilitation on quality of life: a randomized trial in children with unilateral cerebral palsy

Sakzewski L, Carlon S, Shields N, Ziviani J, Ware RS, Boyd RN.

Dev Med Child Neurol. 2012 May;54(5):415-23. doi: 10.1111/j.1469-8749.2012.04272.x. Epub 2012 Mar 17.

A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy

Horvath R, Holinski-Feder E, Neeve VC, Pyle A, Griffin H, Ashok D, Foley C, Hudson G, Rautenstrauss B, Nürnberg G, Nürnberg P, Kortler J, Neitzel B, Bässmann I, Rahman T, Keavney B, Loughlin J, Hambleton S, Schoser B, Lochmüller H, Santibanez-Koref M, Chinnery PF.

Mov Disord. 2012 May;27(6):789-93. doi: 10.1002/mds.24980. Epub 2012 Apr 16.

Do botulinum toxins have a role in the management of neuropathic pain?: a focused review

Francisco GE, Tan H, Green M.

Am J Phys Med Rehabil. 2012 Oct;91(10):899-909. doi: 10.1097/PHM.0b013e31825a134b.

Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations

Turner M, Nguyen HS, Cohen-Gadol AA.

J Neurosurg Pediatr. 2012 Oct;10(4):315-9. doi: 10.3171/2012.6.PEDS11456. Epub 2012 Aug 3.

An overview of drug therapies used in the treatment of dystonia and spasticity in children

Tickner N, Apps JR, Keady S, Sutcliffe AG.

Arch Dis Child Educ Pract Ed. 2012 Dec;97(6):230-5. doi: 10.1136/archdischild-2011-301170. Epub 2012 Aug 15.

Spasticity: pathophysiology, evaluation and management

Kheder A, Nair KP.

Pract Neurol. 2012 Oct;12(5):289-98. doi: 10.1136/practneurol-2011-000155.

Immunogenicity of botulinum toxins

Naumann M, Boo LM, Ackerman AH, Gallagher CJ.

J Neural Transm (Vienna). 2013 Feb;120(2):275-90. doi: 10.1007/s00702-012-0893-9. Epub 2012 Sep 25.

POLR3-Related Leukodystrophy

Bernard G, Vanderver A.

2012 Aug 2 [updated 2017 May 11]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia

Tezenas du Montcel S, Charles P, Goizet C, Marelli C, Ribai P, Vincitorio C, Anheim M, Guyant-Maréchal L, Le Bayon A, Vandenberghe N, Tchikviladzé M, Devos D, Le Ber I, N'Guyen K, Cazeneuve C, Tallaksen C, Brice A, Durr A.

Arch Neurol. 2012 Apr;69(4):500-8. doi: 10.1001/archneurol.2011.2713.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381.

Long-term follow-up of four patients affected by HHH syndrome

Kim SZ, Song WJ, Nyhan WL, Ficicioglu C, Mandell R, Shih VE.

Clin Chim Acta. 2012 Jul 11;413(13-14):1151-5. doi: 10.1016/j.cca.2012.03.015. Epub 2012 Mar 23.

MCT8 deficiency: extrapyramidal symptoms and delayed myelination as prominent features

Tonduti D, Vanderver A, Berardinelli A, Schmidt JL, Collins CD, Novara F, Genni AD, Mita A, Triulzi F, Brunstrom-Hernandez JE, Zuffardi O, Balottin U, Orcesi S.

J Child Neurol. 2013 Jun;28(6):795-800. doi: 10.1177/0883073812450944. Epub 2012 Jul 17.

Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke

Santamato A, Panza F, Ranieri M, Frisardi V, Micello MF, Filoni S, Fortunato F, Intiso D, Basciani M, Logroscino G, Fiore P.

J Neural Transm (Vienna). 2013 Mar;120(3):469-76. doi: 10.1007/s00702-012-0892-x. Epub 2012 Sep 7.

Spasticity

Dietz V, Sinkjaer T.

Handb Clin Neurol. 2012;109:197-211. doi: 10.1016/B978-0-444-52137-8.00012-7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias